Real time non-invasive imaging of receptor-ligand interactions in vivo

2003 ◽  
Vol 90 (3) ◽  
pp. 454-463 ◽  
Author(s):  
Paul Winnard, ◽  
Venu Raman
2015 ◽  
Vol 51 (32) ◽  
pp. 6948-6951 ◽  
Author(s):  
Yanfeng Zhang ◽  
Qian Yin ◽  
Jonathan Yen ◽  
Joanne Li ◽  
Hanze Ying ◽  
...  

Anin vitroandin vivodrug-reporting system is developed for real-time monitoring of drug release via the analysis of the concurrently released near-infrared fluorescence dye.


2018 ◽  
Vol 8 (1) ◽  
Author(s):  
José M. S. Fernández-Calleja ◽  
Prokopis Konstanti ◽  
Hans J. M. Swarts ◽  
Lianne M. S. Bouwman ◽  
Vicenta Garcia-Campayo ◽  
...  

2019 ◽  
Author(s):  
Alena Rudkouskaya ◽  
Nattawut Sinsuebphon ◽  
Marien Ochoa ◽  
Joe E. Mazurkiewicz ◽  
Xavier Intes ◽  
...  

AbstractFollowing an ever-increased focus on personalized medicine, there is a continuing need to develop preclinical molecular imaging modalities to guide the development and optimization of targeted therapies. To date, non-invasive quantitative imaging modalities that can comprehensively assess simultaneous cellular drug delivery efficacy and therapeutic response are lacking. In this regard, Near-Infrared (NIR) Macroscopic Fluorescence Lifetime Förster Resonance Energy Transfer (MFLI-FRET) imaging offers a unique method to robustly quantify receptor-ligand engagement in vivo and subsequent intracellular internalization, which is critical to assess the delivery efficacy of targeted therapeutics. However, implementation of multiplexing optical imaging with FRET in vivo is challenging to achieve due to spectral crowding and cross-contamination. Herein, we report on a strategy that relies on a dark quencher that enables simultaneous assessment of receptor-ligand engagement and tumor metabolism in intact live mice. First, we establish that IRDye QC-1 (QC-1) is an effective NIR dark acceptor for the FRET-induced quenching of donor Alexa Fluor 700 (AF700) using in vitro NIR FLI microscopy and in vivo wide-field MFLI imaging. Second, we report on simultaneous in vivo imaging of the metabolic probe IRDye 800CW 2-deoxyglucose (2-DG) and MFLI-FRET imaging of NIR-labeled transferrin FRET pair (Tf-AF700/Tf-QC-1) uptake in tumors. Such multiplexed imaging revealed an inverse relationship between 2-DG uptake and Tf intracellular delivery, suggesting that 2-DG signal may predict the efficacy of intracellular targeted delivery. Overall, our methodology enables for the first time simultaneous non-invasive monitoring of intracellular drug delivery and metabolic response in preclinical studies.


2013 ◽  
Vol 48 ◽  
pp. 1-13 ◽  
Author(s):  
Aijuan Liu ◽  
Shumei Zhai ◽  
Bin Zhang ◽  
Bing Yan

2016 ◽  
Vol 4 (48) ◽  
pp. 7793-7812 ◽  
Author(s):  
Kewen Lei ◽  
Qian Ma ◽  
Lin Yu ◽  
Jiandong Ding

In vivo imaging of biomedical hydrogels enables real-time and non-invasive visualization of the status of structure and function of hydrogels.


2011 ◽  
Vol 34 (3) ◽  
pp. 81-98 ◽  
Author(s):  
Jonathan T. C. Liu ◽  
Nathan O. Loewke ◽  
Michael J. Mandella ◽  
Richard M. Levenson ◽  
James M. Crawford ◽  
...  

Advances in optical designs are enabling the development of miniature microscopes that can examine tissue in situ for early anatomic and molecular indicators of disease, in real time, and at cellular resolution. These new devices will lead to major changes in how diseases are detected and managed, driving a shift from today's diagnostic paradigm of biopsy followed by histopathology and recommended therapy, to non-invasive point-of-care diagnosis with possible same-session definitive treatment. This shift may have major implications for the training requirements of future physicians to enable them to interpret real-timein vivomicroscopic data, and will also shape the emerging fields of telepathology and telemedicine. Implementation of new technologies into clinical practice is a complex process that requires bridging gaps between clinicians, engineers and scientists. This article provides a forward-looking discussion of these issues, with a focus on malignant and pre-malignant lesions, by first highlighting some of the clinical areas where point-of-carein vivomicroscopy could address unmet needs, and then by reviewing the technological challenges that are being addressed, or need to be addressed, forin vivomicroscopy to become a standard clinical tool.


Sign in / Sign up

Export Citation Format

Share Document